Clinical Trials
11 trialsNCT01075321 2020-10-22
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Mayo Clinic
Phase 1/2 Completed
NCT00898963 2020-07-31
Biomarkers in Patients With Stage III or Stage IV Follicular Lymphoma Treated on Clinical Trial E-1496
Eastern Cooperative Oncology Group
Completed
NCT00691652 2019-11-27
Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
Phase 1/2 Terminated
NCT00904514 2018-10-05
Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial
National Institutes of Health Clinical Center (CC)
Terminated
NCT00601718 2017-05-25
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
Phase 1/2 Completed
NCT00049504 2017-05-17
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT01150643 2017-05-17
Biomarkers in Samples From Patients With Follicular Lymphoma Treated With Rituximab
Eastern Cooperative Oncology Group
Completed
NCT01381705 2017-05-17
Biomarkers in Predicting Response to Rituximab Treatment in Samples From Patients With Indolent Follicular Lymphoma
Eastern Cooperative Oncology Group
Completed
NCT01406782 2017-05-17
DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
Eastern Cooperative Oncology Group
Completed
NCT00893477 2013-08-02
GM-CSF and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00896519 2013-08-02
GM-CSF, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Advanced Follicular Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 2 Unknown